Traynor Capital Management, Inc. Galectin Therapeutics Inc Transaction History
Traynor Capital Management, Inc.
- $1.6 Billion
- Q3 2024
A detailed history of Traynor Capital Management, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Traynor Capital Management, Inc. holds 42,871 shares of GALT stock, worth $116,609. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,871
Previous 42,871
-0.0%
Holding current value
$116,609
Previous $96,000
21.88%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
90Shares Held
9.57MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$5.81 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$4.25 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$3.22 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$2.35 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.31 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $162M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...